Menu
Search
|

Menu

Close
X

T2 Biosystems Inc TTOO.OQ (NASDAQ Stock Exchange Global Market)

4.46 USD
-- (--)
As of Feb 20
chart
Previous Close 4.46
Open --
Volume --
3m Avg Volume 42,880
Today’s High --
Today’s Low --
52 Week High 6.97
52 Week Low 2.51
Shares Outstanding (mil) 35.82
Market Capitalization (mil) 159.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.17 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
3
FY16
4
FY15
3
EPS (USD)
FY17
-1.434
FY16
-2.120
FY15
-2.208
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
40.82
8.67
Price to Book (MRQ)
vs sector
8.81
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
228.97
15.38
LT Debt to Equity (MRQ)
vs sector
221.16
12.01
Return on Investment (TTM)
vs sector
-88.46
13.57
Return on Equity (TTM)
vs sector
-171.11
15.19

EXECUTIVE LEADERSHIP

John McDonough
President, Chief Executive Officer, Director, Since 2007
Salary: $425,466.00
Bonus: --
Michael Cima
Co-Founder, Independent Director, Since 2006
Salary: --
Bonus: --
John Sprague
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Joanne Spadoro
Chief Operations Officer, Since 2016
Salary: --
Bonus: --
Rahul Dhanda
Senior Vice President - Corporate Development, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

101 Hartwell Ave
LEXINGTON   MA   02421-3125

Phone: +1781.4571200

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

SPONSORED STORIES